Getting real about valuations in biotech

Nature Biotechnology

Volumn 23, Issue 4, 2005, Pages 423-428

  Villiger, Ralph ^a   Bogdan, Boris ^a  

^a Avance   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; MANAGERS; PROJECT MANAGEMENT;

LICENSE; PROJECT MANAGERS;

DRUG PRODUCTS;

BIOTECHNOLOGY; COMMERCIAL PHENOMENA; COMMODIFICATION; DRUG INDUSTRY; FINANCIAL MANAGEMENT; LICENSING; MARKETING; PATENT; PRIORITY JOURNAL; REVIEW; ARTICLE; BUDGET; CONTRACT; ECONOMICS;

BIOTECHNOLOGY; BUDGETS; CONTRACTS; DRUG INDUSTRY; LICENSURE;

EID: 23644456717     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0405-423     Document Type: Review

References (5)

1. Fernández, P., Valuing real options: frequently made errors, Journal of Financial Transformations, 13, 77-81 (2005).
2. Dimasi, J.A. Risks in new drug development: approval success rates for investigational drugs. Clin. Pharmacol. Ther. 69, 297-307 (2001).
3. Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711-715 (2004).
4. Tufts Center for the Study of Drug Development. Outlook 2005. Tufts Outlook Report. (Tufts Center, Medford, MA, USA, 2005).
5. Grabowski, H.G. & Vernon, J. The distribution of sales revenues from pharmaceutical innovation. Pharmacoeconomics 18 Suppl 1, 21-32 (2000).